Sustainability in drug development is moving beyond reporting. Increasingly, it is becoming part of how manufacturing strategies are designed from the outset. In this Pharma’s Almanac industry roundtable, Arjen Akerman shares his perspective on how small-batch manufacturing, efficient formulation development and localized supply models can help reduce material use and waste while maintaining the flexibility, speed and quality required in early phase development.